Selegiline for Health & Longevity

Evidence Review created on 04/28/2026 using AI4L / Opus 4.7

Also known as: Deprenyl, L-Deprenyl, (-)-Deprenyl, Eldepryl, Zelapar, Emsam, Jumex, Anipryl

Motivation

Selegiline is a prescription compound originally developed in Hungary in the 1960s as a selective inhibitor of an enzyme that breaks down dopamine in the brain. It is approved for the treatment of Parkinson’s disease and, in transdermal form, for major depressive disorder, but interest in selegiline within longevity-oriented circles arises from a different lineage: a series of animal studies in which low doses of the compound were reported to consistently extend the average lifespan of treated rodents and dogs.

Beyond the lifespan signal, the compound’s primary mechanism centers on preserving dopamine-related neuronal function as the brain ages. These findings have placed it among the more enduring candidates for pharmacological longevity intervention, despite the absence of any randomized human trial powered for lifespan or healthspan endpoints.

This review examines selegiline as a health and longevity intervention, surveying the human and animal evidence, the principal mechanisms of action, the safety and interaction profile, the therapeutic protocols proposed by the compound’s original developer and by current practitioners, and the substantial gaps in evidence that remain.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Selegiline

The Grokipedia entry summarizes selegiline as a selective irreversible MAO-B inhibitor, its FDA-approved indications for Parkinson’s disease and major depressive disorder, the available formulations (oral tablets, orally disintegrating tablets, transdermal patch), its metabolism into active metabolites including levomethamphetamine and levoamphetamine, and the principal safety considerations including the loss of MAO-B selectivity at higher doses.

Examine

No dedicated Examine.com article for selegiline was found. Examine.com does not typically maintain comprehensive pages for prescription medications, focusing instead on dietary supplements and nutrition; the absence of a dedicated page is consistent with selegiline’s status as a prescription pharmaceutical.

ConsumerLab

No dedicated ConsumerLab article for selegiline was found. ConsumerLab does not typically cover prescription medications, focusing instead on independent product testing of dietary supplements and consumer health products.

Systematic Reviews

This section lists systematic reviews and meta-analyses evaluating selegiline across its principal indications and aging-relevant outcomes.

Efficacy and safety of selegiline for the treatment of Parkinson’s disease: A systematic review and meta-analysis - Wang et al., 2023

A systematic review and meta-analysis of 27 RCTs (randomized controlled trials, studies that randomly assign participants to a treatment or a control group) and 11 observational studies. Selegiline produced progressively stronger improvement in total UPDRS (Unified Parkinson’s Disease Rating Scale, the standard clinical measure of Parkinson’s disease severity) score with increasing treatment duration, ranging from a mean difference of -3.56 at 1 month to -11.06 at 60 months versus placebo, but had a higher rate of neuropsychiatric adverse events (OR (odds ratio, the odds of an event in one group relative to another) 1.36).
A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson’s disease - Binde et al., 2018

A network meta-analysis comparing rasagiline, selegiline, and safinamide across 27 RCTs. All three MAO-B (monoamine oxidase type B, the brain enzyme that preferentially breaks down dopamine) inhibitors were efficacious as monotherapy versus placebo. When given in combination with levodopa, selegiline ranked as the most effective of the three with a relative effect of 1.532 (95% CI (confidence interval, the range within which the true effect likely falls) 1.337–1.757).
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis - Binde et al., 2020

A network meta-analysis of 79 RCTs comparing four dopamine agonists and three MAO-B inhibitors. All examined drugs except safinamide were effective as monotherapy compared with placebo. In combination with levodopa, selegiline had the largest relative effect (2.316; 95% CI 1.819–2.951), positioning it ahead of pramipexole, ropinirole, and rasagiline as adjunctive therapy.
Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations - Rossano et al., 2023

A meta-analysis of 23 trials covering depressive disorders, schizophrenia, ADHD (attention-deficit/hyperactivity disorder), and smoking cessation. Selegiline outperformed placebo for depressive symptom reduction (SMD (standardized mean difference, an effect size scaled by variability) -0.96; 95% CI -1.78 to -0.14) and atypical-depression response (RR (relative risk, the ratio of event probability in the treatment group versus the control group) 2.23) but did not outperform placebo in schizophrenia, ADHD, or smoking cessation.
Effect of selegiline on mortality in patients with Parkinson’s disease: a meta-analysis - Olanow et al., 1998

A pooled analysis of five long-term, randomized, placebo-controlled trials totaling 589 patients with mean follow-up of 4.1 years. Selegiline did not increase mortality (HR (hazard ratio, the relative rate at which an event occurs over time) 1.02; 95% CI 0.44–2.37), addressing the earlier mortality concern raised by the Parkinson’s Disease Research Group of the United Kingdom.

Mechanism of Action

Selegiline is a selective, irreversible inhibitor of MAO-B, the enzyme primarily responsible for the deamination of dopamine, phenylethylamine, and benzylamine in the human brain. The principal pharmacological action and the basis of its clinical utility are interlinked but distinguishable from one another, and the longevity-relevant mechanisms extend beyond MAO-B inhibition alone.

Selective MAO-B inhibition: At oral doses of 10 mg/day or below, selegiline binds covalently and irreversibly to MAO-B, sparing MAO-A (which preferentially metabolizes serotonin and norepinephrine). This prevents the dietary tyramine reaction (the “cheese effect”) that occurs with non-selective MAO inhibitors. Recovery of MAO-B activity after discontinuation requires de novo enzyme synthesis, taking approximately 2–3 weeks. At doses above 10 mg/day, selectivity is progressively lost and MAO-A is also inhibited.
Catecholaminergic activity enhancer (CAE) effect: Independent of MAO-B inhibition, selegiline enhances impulse-mediated release of catecholamines (dopamine, norepinephrine) from neurons at doses far below those needed for enzyme inhibition. This effect, identified by selegiline’s developer, is proposed by the Knoll laboratory as the principal mechanism underlying lifespan extension in animal studies. Whether the CAE effect operates in humans at meaningful magnitudes remains debated.
Antioxidant enzyme upregulation: Selegiline increases superoxide dismutase (SOD, an enzyme that neutralizes reactive oxygen species), catalase, and glutathione peroxidase activity in brain tissue, reducing oxidative damage to neurons and mitochondria. This effect has been documented in rodent striatum and substantia nigra (the dopaminergic midbrain region most vulnerable in Parkinson’s disease).
Mitochondrial protection: The compound stabilizes the mitochondrial permeability transition pore and modulates pro-apoptotic and anti-apoptotic signaling, biasing cellular responses to stress toward survival. The desmethyl-selegiline metabolite has been studied for direct anti-apoptotic activity at low concentrations.
Neurotrophic factor induction: Selegiline raises levels of NGF (nerve growth factor, a protein supporting neuron survival and growth), BDNF (brain-derived neurotrophic factor, a protein critical for learning, memory, and neuronal health), and GDNF (glial cell line-derived neurotrophic factor), which preferentially supports dopaminergic neurons. These changes have been documented in rodent and primate studies and contribute to the neuroprotective hypothesis.
Immune modulation: Animal studies and limited human data show increased natural killer cell activity, enhanced T-cell function, and altered cytokine profiles with selegiline treatment, providing a plausible mechanism for some of the broader effects on age-related decline.

Where competing mechanistic accounts exist, the original Knoll hypothesis emphasizes the CAE effect at very low doses; alternative accounts emphasize MAO-B inhibition itself as the primary driver, with antioxidant and neurotrophic effects as downstream consequences. These are not mutually exclusive, and the relative contributions remain unresolved.

Key pharmacological properties:

Half-life: The parent compound has a plasma half-life of approximately 1.2–10 hours; metabolite half-lives range from 2 to 21 hours. Because MAO-B inhibition is irreversible, the pharmacodynamic effect substantially outlasts plasma concentrations.
Selectivity: MAO-B selective at oral doses ≤10 mg/day; loses selectivity at higher oral doses or with the transdermal patch at 9 mg/24h and 12 mg/24h.
Tissue distribution: Highly lipophilic; distributes broadly into brain tissue. Plasma protein binding is approximately 85–90%.
Metabolism: Extensive first-pass hepatic metabolism, primarily via CYP2B6 (cytochrome P450 2B6, a liver enzyme involved in drug metabolism) with secondary contributions from CYP3A4 (cytochrome P450 3A4, a liver enzyme responsible for metabolizing many drugs) and CYP2A6 (cytochrome P450 2A6, another liver metabolic enzyme). Primary active metabolites are N-desmethylselegiline, levomethamphetamine, and levoamphetamine. Oral bioavailability is low (approximately 4–10%); the transdermal route bypasses first-pass metabolism, achieving substantially higher systemic concentrations.

Historical Context & Evolution

Selegiline was synthesized in 1962 at Chinoin Pharmaceuticals in Budapest, Hungary, by chemist Zoltan Ecseri under the direction of pharmacologist Jozsef Knoll. It was investigated initially as a potential antidepressant in the methamphetamine analog series and designated E-250. Knoll’s recognition of its selective MAO-B inhibition distinguished it from existing non-selective MAO inhibitors, whose dietary interactions had limited clinical use.

The compound entered clinical practice in Hungary in 1977 for Parkinson’s disease, and in 1989 it was approved by the United States Food and Drug Administration under the brand name Eldepryl as an adjunct to levodopa in Parkinson’s disease.

The pivotal shift toward longevity interest came in 1988, when Knoll published a study showing that elderly male rats treated with low-dose selegiline lived significantly longer than saline-treated controls, with the longest-living selegiline-treated rat surviving beyond the previously established maximum lifespan of the strain. The result was subsequently corroborated by Milgram and colleagues in aged rats, by Kitani and colleagues across multiple strains and species, and by veterinary studies in aged dogs in which selegiline doubled survival rates and improved cognitive scores. These animal data led to the veterinary approval of selegiline (Anipryl) for canine cognitive dysfunction syndrome.

The 1989 DATATOP trial (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism) demonstrated that selegiline delayed the need for levodopa in early Parkinson’s disease. The original investigators interpreted this as evidence of a neuroprotective effect, but subsequent re-analyses argued that the delayed need for levodopa could be explained by symptomatic benefit alone. The neuroprotective question has not been definitively resolved, and rather than treating either interpretation as the settled view, the available data support both effects in different proportions.

In 1995, the United Kingdom Parkinson’s Disease Research Group published a study reporting increased mortality among patients receiving levodopa plus selegiline compared to levodopa alone. The finding generated significant clinical concern. A 1998 meta-analysis of five long-term randomized trials by Olanow and colleagues did not confirm the mortality signal (HR 1.02), and the original signal was attributed to methodological limitations, but the episode illustrates how a single trial can durably shape clinical practice and how pooled evidence can shift the picture.

The transdermal patch (Emsam) was approved by the FDA in 2006 for major depressive disorder. The patch bypasses first-pass metabolism, raising systemic concentrations and producing combined MAO-A/MAO-B inhibition at higher doses, which both expands the antidepressant action and reintroduces the tyramine restriction at 9 mg/24h and 12 mg/24h.

The longevity research community, including the Life Extension Foundation (an advocacy organization with commercial revenue from longevity-related publications and products, representing a relevant conflict of interest in its policy positions), has advocated for broader access to low-dose selegiline since the 1990s, citing the consistency of the mammalian lifespan data and the relatively favorable safety profile at low oral doses. As of early 2026, no randomized human trial has been registered or completed with lifespan or healthspan as a primary endpoint.

Expected Benefits

A dedicated search for selegiline’s complete benefit profile was performed across PubMed, drug references, FDA prescribing information for Eldepryl, Zelapar, and Emsam, longevity-oriented practitioner reviews, and systematic reviews before drafting this section.

High 🟩 🟩 🟩

Symptom Improvement in Parkinson’s Disease

Selegiline is FDA-approved as both monotherapy in early Parkinson’s disease and as an adjunct to levodopa in more advanced disease. Multiple large RCTs and pooled analyses confirm motor symptom improvement. The 2018 Binde network meta-analysis ranked selegiline as the most effective MAO-B inhibitor when combined with levodopa. The 2023 Wang systematic review demonstrated progressively larger improvement in UPDRS scores with longer treatment duration. While outside the primary longevity use case, this established efficacy underwrites the drug’s clinical legitimacy and supports the dopaminergic mechanism that informs longevity-oriented hypotheses.

Magnitude: Mean reduction of 3.5–11 points on total UPDRS score versus placebo, depending on treatment duration of 1–60 months.

Antidepressant Effect (Transdermal Selegiline)

The transdermal patch (Emsam) is FDA-approved for major depressive disorder. The 2023 Rossano meta-analysis showed a robust effect on depressive symptom reduction (SMD -0.96) and an especially strong effect in atypical depression (response RR 2.23). The mechanism at the higher systemic concentrations achieved by the patch involves combined MAO-A and MAO-B inhibition, raising dopamine, norepinephrine, and serotonin availability.

Magnitude: SMD -0.96 for depressive symptom reduction in pooled trials; response RR 2.23 in atypical depression.

Medium 🟩 🟩

Lifespan Extension in Mammalian Models ⚠️ Conflicted

Multiple animal studies across rats, mice, dogs, and hamsters have reported significant extension of average lifespan with low-dose selegiline. The original 1988 Knoll study in male rats reported that the average lifespan rose from approximately 147 weeks (saline controls) to approximately 198 weeks (selegiline), with the longest-living selegiline-treated rat surviving 226 weeks. Replications by Milgram, Kitani, and others have generally confirmed average lifespan extension on the order of 15–34%, with effects varying by strain, sex, and dose. However, several replication attempts have produced null or smaller effects, and the magnitude is heterogeneous; most studies used male animals, and results in females have been less consistent. No human lifespan trial has been conducted, so translation to human longevity remains a hypothesis rather than a demonstrated outcome.

Magnitude: Approximately 15–34% increase in average lifespan in successful rodent studies; effects are heterogeneous across strains, sex, and dose.

Neuroprotective and Cognitive Effects

In animal models, selegiline upregulates antioxidant enzymes (SOD, catalase), increases neurotrophic factors (NGF, BDNF, GDNF), reduces oxidative damage, and stabilizes mitochondrial function. In the DATATOP trial, selegiline delayed the need for levodopa in early Parkinson’s disease, a finding originally interpreted as neuroprotective and now understood as a combined symptomatic and possibly disease-modifying effect. In aged dogs with canine cognitive dysfunction syndrome, selegiline produced improvement in cognitive scores sufficient to support a veterinary indication. Human evidence in non-Parkinson’s populations is limited.

Magnitude: Not quantified in available studies for healthy humans; in aged dogs, response rates of approximately 70% on cognitive measures have been reported.

Low 🟩

Preservation of Dopaminergic Tone in Aging

MAO-B activity in the human brain rises with age, with approximately a 2–3 fold increase in activity from young adulthood to the 7th–8th decade. The downstream consequence is accelerated dopamine catabolism, which has been linked to age-related declines in motor speed, motivation, working memory, and reward processing. Selegiline directly counteracts this enzyme rise, restoring synaptic dopamine. While the age-related rise in MAO-B is well documented, the clinical effects of pharmacologically reversing it in healthy aging adults have not been tested in large randomized trials.

Magnitude: Approximately 40–70% increase in synaptic dopamine availability at standard MAO-B inhibitory doses.

Immune Function Support

Animal studies and limited human data show increased natural killer cell activity, enhanced T-cell proliferation, and modulation of cytokine production with selegiline. This has been hypothesized to contribute to its overall protective profile, particularly given the well-documented age-related decline in immune competence (immunosenescence). Direct evidence linking these immunological changes to clinical endpoints in humans is sparse.

Magnitude: Not quantified in available studies.

Speculative 🟨

Tumor Manifestation Suppression

A longevity study by Knoll and colleagues incidentally observed substantially lower tumor manifestation rates in selegiline-treated rats compared to saline-treated controls, leading to the proposal of a previously unrecognized tumor-suppressive regulatory mechanism. The finding has not been independently replicated in published peer-reviewed work, and no human data support this effect.

Sexual Function and Drive

Animal studies and anecdotal practitioner reports have suggested that low-dose selegiline may sustain sexual activity and drive, particularly in older male rats where it has been described as restoring copulatory behavior. The basis is mechanistic (preserved dopaminergic tone) rather than clinical, and no controlled human trials evaluate selegiline for sexual function in otherwise healthy aging adults.

Benefit-Modifying Factors

Age at initiation: In aggregate, animal studies and the Knoll concept suggest that initiation in middle age (corresponding to the onset of measurable dopaminergic decline) may be most relevant; in rodent studies, both early and late initiation have produced lifespan effects, with some pooled analyses suggesting larger effects with later initiation.
Baseline biomarker levels: Individuals with biomarkers of reduced dopaminergic function (e.g., low CSF (cerebrospinal fluid, the fluid surrounding the brain and spinal cord) homovanillic acid, a dopamine metabolite, or elevated MAO-B activity on PET (positron emission tomography, a brain imaging technique)) may derive greater benefit. These measures are not part of routine practice.
Sex-based differences: Most lifespan studies used male animals; female data are more limited. Sex-based differences in MAO-B expression and CYP2B6 activity exist in humans but have not been studied for selegiline longevity outcomes specifically.
Pre-existing health conditions: Individuals with early Parkinson’s disease, atypical depression, or measurable age-related cognitive decline have the strongest evidence base. In healthy individuals, longevity benefit relies on extrapolation from animal data and mechanistic reasoning.
Age-related considerations: Older adults may benefit from the dopaminergic and neuroprotective effects but face higher risks of orthostatic hypotension and drug interactions. Reduced hepatic clearance with age can raise drug exposure.
Genetic polymorphisms: CYP2B6 is highly polymorphic, with poor metabolizers exhibiting higher selegiline plasma levels and ultra-rapid metabolizers exhibiting lower levels. No genotype-specific dosing guideline is established for selegiline.

Potential Risks & Side Effects

A dedicated search for selegiline’s complete side effect profile was performed using FDA prescribing information for Eldepryl, Zelapar, and Emsam, the StatPearls monograph, drugs.com, Mayo Clinic drug references, and the Rossano 2023 meta-analysis before drafting this section.

High 🟥 🟥 🟥

Serotonin Syndrome with Concomitant Serotonergic Drugs

Serotonin syndrome (a potentially life-threatening condition caused by excessive serotonin activity, with agitation, hyperthermia, autonomic instability, and muscle rigidity) can occur when selegiline is combined with SSRIs (selective serotonin reuptake inhibitors, the most commonly prescribed class of antidepressants), SNRIs (serotonin-norepinephrine reuptake inhibitors), tricyclic antidepressants, meperidine, tramadol, dextromethorphan, or St. John’s Wort. Although selegiline at standard oral doses is MAO-B selective, the FDA labeling and case literature establish this as an absolute contraindication. The widespread use of antidepressants makes this the single most consequential interaction risk in practice.

Magnitude: Severe serotonin syndrome carries reported case fatality rates of approximately 2–12%; risk is present at any selegiline dose when combined with contraindicated agents.

Insomnia and Sleep Disturbance

Selegiline’s stimulant-like metabolites (levomethamphetamine and levoamphetamine) and direct dopaminergic effects can disrupt sleep onset and continuity, particularly when dosed later in the day. The Rossano 2023 meta-analysis identified insomnia as significantly more common with selegiline than placebo (RR 1.61). For an audience that prioritizes sleep as a longevity foundation, this represents a meaningful and direct risk.

Magnitude: RR 1.61 versus placebo in pooled trials; reported in approximately 10–15% of patients in clinical use.

Medium 🟥 🟥

Orthostatic Hypotension

Selegiline can cause orthostatic hypotension (a drop in blood pressure on standing, leading to dizziness, lightheadedness, or syncope). The mechanism involves altered catecholamine handling and sympathetic effects of the metabolites. The risk is greater with the transdermal patch and in older adults.

Magnitude: Reported in approximately 3–10% of patients; higher with the transdermal formulation and at older ages.

Nausea and Gastrointestinal Effects

Nausea, dry mouth, and abdominal discomfort are commonly reported. Most are mild, dose-dependent, and tend to attenuate with continued use.

Magnitude: Nausea in approximately 7–11% of patients in clinical trials; dry mouth in approximately 4–8%.

Application-Site Reactions (Transdermal)

The transdermal patch produces local skin reactions (erythema, pruritus, irritation) at higher rates than placebo patches. The Rossano 2023 meta-analysis estimated a relative risk of 1.81.

Magnitude: RR 1.81 versus placebo for application-site reactions in transdermal trials.

Low 🟥

Hypertensive Crisis from Tyramine Interaction

At oral doses ≤10 mg/day, MAO-B selectivity is preserved and clinically significant tyramine interactions are rare. At higher oral doses, with the transdermal patch at 9 mg/24h and 12 mg/24h, or with concomitant sympathomimetic drugs, MAO-A inhibition introduces hypertensive crisis risk after consumption of tyramine-rich foods (aged cheese, cured meats, fermented foods, draft beer, soy sauce). Hypertensive crisis (sudden severe blood pressure elevation that can cause stroke or organ damage) is rare but potentially life-threatening.

Magnitude: Extremely rare at oral doses ≤10 mg/day; dietary restriction is required at higher oral doses and at transdermal doses ≥9 mg/24h.

Dyskinesia in Patients on Levodopa

When selegiline is added to levodopa, the additional dopaminergic enhancement can increase the incidence of dyskinesia (abnormal involuntary movements). This is primarily relevant to Parkinson’s disease patients, not to off-label longevity use at low doses, but is documented in the Wang 2023 systematic review.

Magnitude: Approximately 2–5% increase in dyskinesia incidence when added to levodopa.

Headache and Dizziness

Reported across clinical trials, generally mild and transient. The Rossano 2023 meta-analysis did not find a significant increase in headache with selegiline versus placebo, but individual trials report it among the most common general adverse events.

Magnitude: Headache in approximately 4–7% of patients; dizziness in approximately 3–7%.

Speculative 🟨

Impulse Control Disorders

All dopaminergic compounds carry a theoretical risk of impulse control disorders (pathological gambling, hypersexuality, compulsive shopping, binge eating) through enhanced reward signaling. Case reports exist for selegiline. The risk appears lower than with direct dopamine receptor agonists (pramipexole, ropinirole), but at higher doses or in susceptible individuals it cannot be excluded.

Long-Term Effects of Amphetamine Metabolites

Selegiline is metabolized to levomethamphetamine and levoamphetamine. These levo-isomers are substantially less psychoactive than their dextro counterparts (dextroamphetamine is roughly 3–4 times more potent), but accumulate during chronic dosing. Theoretical concerns include cardiovascular load, appetite suppression, and the production of positive results on routine urine drug screens. Long-term cardiovascular and neuropsychiatric consequences in healthy adults using low doses for years to decades have not been characterized.

Risk-Modifying Factors

Concurrent serotonergic medication use: The single largest risk amplifier. Any SSRI, SNRI, tricyclic antidepressant, meperidine, tramadol, dextromethorphan, or serotonergic supplement (St. John’s Wort, 5-HTP, L-tryptophan, SAMe) markedly elevates serotonin syndrome risk.
Age: Older adults are more susceptible to orthostatic hypotension, falls, drug interactions, and reduced hepatic clearance, raising drug exposure for any given dose.
Dose and route: Oral doses above 10 mg/day or transdermal doses at 9 mg/24h and 12 mg/24h lose MAO-B selectivity and introduce tyramine and broader sympathomimetic interaction risk.
Sex-based differences: Women may experience more orthostatic hypotension. CYP2B6 activity can vary by sex, modifying drug exposure.
Pre-existing health conditions: Hepatic impairment increases drug exposure due to reduced metabolism. Cardiovascular disease, history of psychosis or bipolar disorder, and history of substance use disorder warrant caution.
Genetic polymorphisms: Poor CYP2B6 metabolizers have higher selegiline exposure; ultra-rapid metabolizers have lower exposure and higher metabolite levels.
Baseline biomarker levels: Elevated baseline ALT (alanine aminotransferase, a liver enzyme), AST (aspartate aminotransferase, a liver enzyme), or low baseline blood pressure flag individuals at greater risk for hepatic or hemodynamic side effects.

Key Interactions & Contraindications

SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram) and SNRIs (venlafaxine, duloxetine, desvenlafaxine): Serotonin syndrome risk; absolute contraindication. A washout period of 14 days is required between selegiline and SSRI/SNRI in either direction; for fluoxetine, 5 weeks is required because of its long-acting active metabolite. Clinical consequence: severe serotonin syndrome, potentially fatal.
Tricyclic antidepressants (amitriptyline, nortriptyline, imipramine, desipramine): Serotonin syndrome and hypertensive crisis risk. Severity: absolute contraindication at higher selegiline doses; caution at standard oral doses.
Meperidine (Demerol) and tramadol: Serotonin syndrome, potentially fatal. Severity: absolute contraindication with all selegiline formulations and doses.
Dextromethorphan (in many over-the-counter cough remedies): Serotonin syndrome risk. Severity: absolute contraindication. Patients must read OTC (over-the-counter) cough/cold labels to avoid inadvertent exposure.
Other MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue): Hypertensive crisis. Severity: absolute contraindication; 14-day washout in either direction.
Sympathomimetic drugs (pseudoephedrine, phenylephrine, amphetamines, methylphenidate): Hypertensive crisis risk, especially when MAO-A inhibition occurs. Severity: caution at standard oral doses; contraindication at higher doses or transdermal formulations.
Tyramine-rich foods (aged cheese, cured meats, fermented foods, soy sauce, draft beer, red wine): At standard oral doses ≤10 mg/day, clinically significant interaction is rare. At higher oral doses or transdermal doses ≥9 mg/24h, dietary restriction is required. Severity: caution to absolute contraindication depending on dose and route.
Opioids (fentanyl, methadone, oxycodone, tapentadol): Variable serotonergic interaction risk. Severity: caution; absolute contraindication for meperidine and tramadol.
Supplements with serotonergic effects (St. John’s Wort, 5-HTP, L-tryptophan, SAMe (S-adenosylmethionine, a methyl-donor supplement)): Serotonin syndrome risk. Severity: absolute contraindication. Mitigating action: discontinue supplement before initiating selegiline.
Supplements with dopaminergic effects (L-tyrosine, Mucuna pruriens, L-DOPA): Additive dopaminergic stimulation. Severity: caution; monitor for overstimulation, insomnia, and blood pressure changes.
Levodopa/carbidopa: Additive dopaminergic action; increased risk of dyskinesia, hallucinations, orthostatic hypotension. Severity: caution; levodopa dose may require reduction.
Antihypertensives (all classes): Additive blood pressure lowering with orthostatic hypotension risk. Severity: monitor; consider blood pressure logs during initiation.
CYP2B6 inhibitors (clopidogrel, ticlopidine): Reduced selegiline metabolism, raising plasma levels. Severity: monitor; consider dose reduction if added to chronic selegiline.

Populations who should avoid selegiline or use only under specialist supervision:

Concurrent use of any contraindicated serotonergic medication (absolute contraindication)
Pheochromocytoma (a rare adrenal-gland tumor that secretes excess catecholamines; absolute contraindication)
Severe hepatic impairment (Child-Pugh Class C, indicating advanced cirrhosis)
Recent or planned elective surgery using meperidine or other contraindicated anesthetics (within 14 days)
History of psychosis, mania, or bipolar disorder (relative contraindication; dopaminergic stimulation may exacerbate symptoms)
Pregnancy and breastfeeding (insufficient human safety data)

Risk Mitigation Strategies

Comprehensive medication and supplement review before initiation: A line-by-line check of every prescription drug, over-the-counter medication, and supplement is the single most important risk-mitigation step. This addresses serotonin syndrome risk by identifying SSRIs, SNRIs, tricyclics, opioids, dextromethorphan-containing cough products, and serotonergic supplements before any dose is given.
Morning-only dosing: Taking selegiline in the morning (or split between morning and midday for higher Parkinson’s-disease doses), with no doses after 1 PM, mitigates the 10–15% incidence of insomnia from the parent compound and its stimulant metabolites.
Low starting dose with gradual titration: For off-label longevity use, beginning at 1.25–2.5 mg/day and titrating by 1.25–2.5 mg increments every 1–2 weeks based on tolerance keeps doses well within the MAO-B selective range and minimizes side effects. This addresses orthostatic hypotension, nausea, and insomnia.
Oral dose ceiling of 10 mg/day: Maintaining oral doses at or below 10 mg/day preserves MAO-B selectivity and avoids the need for tyramine dietary restriction. This addresses hypertensive crisis risk.
Blood pressure monitoring during the first month: Seated and standing blood pressure measurements at baseline, week 2, and week 4 detect orthostatic hypotension early; dose reduction or discontinuation is appropriate for sustained orthostatic drops greater than 20 mmHg systolic.
OTC cough/cold education: Patients should be specifically educated to read labels and avoid any product containing dextromethorphan during selegiline use, due to serotonin syndrome risk. This addresses an inadvertent-exposure pathway that has caused documented cases.
Periodic interaction re-screening: Whenever a new medication is prescribed or an existing one is changed, the regimen must be re-screened for serotonergic, sympathomimetic, and dopaminergic interactions. This addresses the cumulative risk of polypharmacy in older adults.
Liver function monitoring: Baseline and follow-up ALT and AST (every 6–12 months) detect hepatic stress in a hepatically metabolized drug used long-term. This addresses hepatic adverse events, which are uncommon but documented.

Therapeutic Protocol

Selegiline use falls into two distinct contexts: FDA-approved clinical use (Parkinson’s disease, major depressive disorder) and off-label longevity-oriented use. The protocols differ substantially.

Standard Parkinson’s disease protocol (FDA-approved): Oral selegiline 5 mg twice daily with breakfast and lunch (Eldepryl, generic). Orally disintegrating tablets (Zelapar) start at 1.25 mg once daily before breakfast, increasing to 2.5 mg daily after 6 weeks if needed. Both formulations are dosed in the morning or morning plus midday to avoid insomnia. This regimen was validated in the DATATOP trial and remains the standard.
Standard major depressive disorder protocol (FDA-approved transdermal): Emsam patch starting at 6 mg/24 hours, applied once daily to dry skin on the upper torso, upper thigh, or outer surface of the upper arm. The dose may be increased to 9 mg/24 hours or 12 mg/24 hours after 2–4 weeks based on response. Tyramine dietary restrictions apply at 9 mg/24 hours and 12 mg/24 hours but not at the 6 mg/24 hours dose.
Off-label longevity protocol (Knoll concept): Jozsef Knoll, the pharmacologist who synthesized selegiline and conducted the original lifespan studies, proposed prophylactic low-dose use beginning around age 40–45, corresponding to the onset of measurable age-related dopaminergic decline. The proposed dose is approximately 1 mg/day or 5 mg twice weekly, well below the standard MAO-B inhibitory dose, intended to engage the catecholaminergic activity enhancer effect rather than full enzyme inhibition. Some practitioners recommend 1.25–5 mg/day or 5 mg 2–3 times per week. No randomized human trial has validated any specific longevity dose or schedule.
Best time of day: Morning dosing, no later than 1 PM. This mitigates insomnia from selegiline and its stimulant metabolites.
Half-life and dosing frequency: The parent compound has a short half-life (1.2–10 hours), but irreversible MAO-B inhibition and the 2–3 week recovery time mean the pharmacodynamic effect substantially outlasts plasma exposure. This makes once-daily, intermittent, or even weekly dosing pharmacologically rational for the MAO-B effect. The CAE effect, by contrast, is more closely tied to plasma exposure.
Single dose versus split dose: Standard Parkinson’s disease use is split twice daily (5 mg AM and 5 mg midday). Off-label longevity-oriented use is typically once daily in the morning.
Genetic polymorphisms: CYP2B6 polymorphism affects exposure substantially. Poor metabolizers may benefit from the lower end of any dose range; ultra-rapid metabolizers may metabolize more rapidly into the amphetamine-like metabolites. Routine genotyping is not standard practice but may inform dose adjustment in patients with unexpected responses.
Sex-based differences: Women may have somewhat different CYP2B6 activity and a higher baseline orthostatic hypotension risk. No sex-specific dose has been established for any indication.
Age-related considerations: Adults over 65 should start at the lowest available dose (1.25 mg/day for Zelapar; the 1 mg compounded dose for off-label use) due to increased sensitivity to orthostatic hypotension and altered hepatic clearance. The Knoll concept’s emphasis on initiation in middle age also implies that older adults remain plausible candidates if safety considerations are addressed.
Baseline biomarker considerations: No specific biomarker reliably predicts selegiline response. Individuals with subjective evidence of dopaminergic decline (low motivation, mild cognitive slowing, anhedonia) may be more likely to notice a subjective effect.
Pre-existing conditions: Patients with early Parkinson’s disease, atypical depression, or measurable age-related cognitive decline have the strongest evidence base. Off-label longevity use in healthy individuals rests on extrapolation from animal data and mechanistic reasoning.

Discontinuation & Cycling

Lifelong versus short-term use: In the Knoll longevity framework, low-dose selegiline is intended as a lifelong prophylactic intervention to maintain dopaminergic tone against age-related decline. For Parkinson’s disease and depression, long-term use is standard, with discontinuation guided by clinical course.
Withdrawal effects: Selegiline does not produce a classical withdrawal syndrome. Because MAO-B regeneration takes 2–3 weeks after discontinuation, the pharmacodynamic effect tapers gradually rather than abruptly. In Parkinson’s disease, abrupt discontinuation may unmask worsening motor symptoms; in off-label low-dose use, no formal withdrawal effects are expected.
Tapering protocol: Formal tapering is not required for low-dose selegiline because there is no acute rebound. For patients on higher doses combined with other antiparkinsonian agents, gradual reduction over 1–2 weeks while monitoring symptoms is standard.
Cycling for efficacy maintenance: No cycling protocol is established. The irreversible nature of MAO-B inhibition and the 2–3 week recovery time make daily continuous dosing pharmacologically equivalent to many alternative schedules. Some longevity-oriented practitioners use intermittent dosing (e.g., 2–3 times per week) on the rationale that sub-MAO-B-inhibitory enhancer doses do not require continuous administration.

Sourcing and Quality

Prescription status: Selegiline is a prescription medication in the United States, the European Union, and most regulated markets, dispensed by licensed pharmacies. There is no over-the-counter or supplement form.
Available formulations: Oral tablets and capsules (Eldepryl and generics; 5 mg), orally disintegrating tablets (Zelapar; 1.25 mg), and transdermal patch (Emsam; 6 mg/24h, 9 mg/24h, 12 mg/24h). Generic oral selegiline is widely available and inexpensive in the United States. Zelapar and Emsam are substantially more expensive.
Compounding pharmacies: For off-label longevity doses below the 5 mg standard tablet (e.g., 1, 1.25, or 2.5 mg), compounding pharmacies can prepare custom-strength capsules. PCAB (Pharmacy Compounding Accreditation Board)-accredited compounding pharmacies provide independent quality oversight.
International availability: Selegiline is registered in more than 60 countries under brand names including Jumex, Movergan, Niar, Plurimen, and Anipryl (veterinary). Personal-importation regulations vary by jurisdiction and online pharmacies of unknown provenance should be avoided due to counterfeit risk.
Purity considerations: As a long-established prescription pharmaceutical, selegiline manufactured by regulated companies has consistent quality. Unregulated online sources should be avoided due to risks of counterfeit product, incorrect dosing, and contamination.
Storage: Store at controlled room temperature (20–25 °C / 68–77 °F), away from moisture and light. Transdermal patches should be kept in their sealed pouches until use.

Practical Considerations

Time to effect: For Parkinson’s symptoms, motor improvement may be detectable within days to weeks. For the antidepressant effect (transdermal), several weeks are typically required to assess response. For longevity and neuroprotective effects, the proposed benefits are by their nature long-term and not directly perceptible. Subjective improvements in mood, motivation, and cognitive clarity, when they occur, are typically reported within the first 2–4 weeks.
Common pitfalls: The most consequential pitfall is failing to identify a serotonergic interaction before initiating treatment, particularly with widely prescribed SSRIs and SNRIs and with over-the-counter cough remedies containing dextromethorphan. A second pitfall is dosing late in the day, causing insomnia. A third is exceeding 10 mg/day oral, which silently removes MAO-B selectivity and reintroduces tyramine restriction without a corresponding clinical signal. A fourth is treating off-label longevity dosing as established practice rather than as an extrapolation from animal data and mechanistic reasoning.
Regulatory status: FDA-approved for Parkinson’s disease (oral, orally disintegrating) and major depressive disorder (transdermal). Use for longevity, neuroprotection, or cognitive enhancement in otherwise healthy adults is off-label. Physicians may prescribe off-label but are not obligated to do so, and many will decline.
Cost and accessibility: Generic oral selegiline is inexpensive (typically under $30/month with discount coupons in the United States). Zelapar and Emsam are substantially more expensive and may not be covered by insurance for off-label use. Compounded low-dose capsules add a compounding fee that varies by pharmacy.

Interaction with Foundational Habits

Sleep: Direct, blunting if dosed late. Selegiline’s metabolites and dopaminergic action can disrupt sleep onset and reduce sleep depth when dosed in the afternoon or evening. The interaction is largely avoidable with strict morning-only dosing (no later than 1 PM). Some users report vivid or unusual dreams, attributable to altered monoamine balance during REM (rapid-eye-movement) sleep. Sleep quality should be tracked during initiation and dose changes.
Nutrition: Direct, conditional. At oral doses ≤10 mg/day, no tyramine dietary restriction is required, and selegiline does not interact meaningfully with macronutrient composition. At higher oral doses or with transdermal patches at 9 mg/24h or 12 mg/24h, tyramine-rich foods (aged cheese, cured meats, fermented foods, soy sauce, draft beer, red wine, fava beans) must be avoided to prevent hypertensive crisis. Adequate dietary protein supports tyrosine and phenylalanine availability, the precursors to dopamine.
Exercise: Indirect, modestly potentiating motivation; caution for orthostatic responses. No direct pharmacological interaction with exercise performance or training adaptation is established. The dopaminergic action may modestly increase motivation and exercise drive. Orthostatic hypotension risk warrants caution with rapid postural changes during training, particularly in older adults.
Stress management: Indirect, potentially potentiating resilience. Animal data suggest that selegiline attenuates some stress-induced behavioral deficits and supports dopaminergic tone, which may translate to improved subjective stress tolerance. Direct human evidence is limited. The compound is not a substitute for foundational stress management practices and should be used alongside them.

Monitoring Protocol & Defining Success

Baseline testing is recommended before initiating selegiline to establish reference values and identify contraindications. Ongoing monitoring should occur at week 2, week 4, then every 3–6 months for patients on continued treatment, with hepatic function checked annually if stable.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Resting blood pressure (seated and standing)	Systolic 110–120 mmHg; orthostatic drop <20 mmHg systolic	Detect orthostatic hypotension and overall cardiovascular response	Standing measurement after 1–2 minutes upright; conventional threshold for hypertension is ≥140/90 mmHg
Resting heart rate	50–70 bpm	Detect dopaminergic and metabolite-related cardiovascular effects	Measure before morning dose; sustained increase >10 bpm warrants evaluation
ALT	<25 U/L (men), <22 U/L (women)	Monitor hepatic function in a hepatically metabolized drug	ALT (alanine aminotransferase); conventional range up to 40 U/L; functional range catches earlier elevation
AST	<25 U/L (men), <22 U/L (women)	Monitor hepatic function	AST (aspartate aminotransferase); best interpreted alongside ALT; isolated AST elevation may reflect muscle source
Complete metabolic panel	Within standard ranges	Baseline assessment of hepatic and renal function	Includes electrolytes, BUN (blood urea nitrogen, a marker of kidney function), creatinine; fasting draw
CBC with differential	Within standard reference ranges	Establish baseline hematologic and immune status	CBC (complete blood count); annual repeat is sufficient
PHQ-9 or equivalent mood scale	Stable or improved from baseline	Track mood and motivation changes during treatment	PHQ-9 (Patient Health Questionnaire-9, a standardized 9-item depression screen); useful especially in transdermal use for depression

Qualitative markers to monitor:

Sleep quality: Subjective sleep onset, duration, and restorative quality should remain stable or improve; deterioration warrants dose timing review
Mood and motivation: Stable or modestly improved; substantial changes in either direction warrant assessment
Cognitive clarity: Subjective sense of mental sharpness and processing speed; improvements typically appear within 2–4 weeks if at all
Energy and physical drive: Stable or modestly improved
Impulse control: Watch for any new pattern of compulsive gambling, shopping, eating, or sexual behavior, particularly at higher doses
Skin (transdermal users): No persistent erythema, blistering, or new rash at application sites

Emerging Research

Skin tolerability of new transdermal formulation: A Phase 1 trial (NCT07452692) is evaluating skin irritation and sensitization of a new selegiline transdermal delivery system compared with the marketed Emsam patch in 230 healthy subjects, sponsored by Corium Innovations (industry sponsor with a direct financial interest in approval of its generic transdermal product) and scheduled to begin July 2026. The trial is focused on dermatological tolerability rather than efficacy but signals continued commercial development of the transdermal route.
Bioavailability of selegiline transdermal vs. Emsam: A completed pilot pharmacokinetic study (NCT06607744) of 12 healthy subjects compared a selegiline transdermal system at 6 mg/24h to Emsam, also sponsored by Corium Innovations (same commercial conflict of interest), supporting the bioequivalence pathway for a new commercial product.
Selegiline for excessive daytime sleepiness in Parkinson’s disease: A completed Phase 4 trial (NCT04870372) at the Second Affiliated Hospital of Soochow University evaluated selegiline for excessive daytime sleepiness in 141 Parkinson’s disease patients, examining a non-motor symptom domain that is highly relevant to quality of life in aging populations.
Selegiline plus docetaxel for metastatic prostate cancer: A Phase 2 trial (NCT04586543) tested selegiline as an adjunct to docetaxel chemotherapy in 110 patients with metastatic castration-resistant prostate adenocarcinoma. The rationale draws on monoamine oxidase activity in prostate tumor biology, opening a research direction distinct from the neurological indications.
Selegiline and reward processing in healthy adults: A trial at the University of Oxford (NCT04130087) studied 54 healthy participants given 10 mg selegiline versus placebo to evaluate dopaminergic effects on reward learning and approach motivation, providing rare human data on dopaminergic mechanisms in non-patient populations.
Lifespan and healthspan trials in humans: As of early 2026, no randomized human trial registered on clinicaltrials.gov uses lifespan or composite healthspan as a primary endpoint for selegiline. Calls for such trials have been made repeatedly in the literature (Knoll & Miklya, 2016), but the lack of patent protection on generic selegiline and the long duration required for lifespan endpoints have limited commercial sponsorship. This is the most consequential evidence gap for the longevity use case.
Catecholaminergic activity enhancer pharmacology: Continued mechanistic research on the CAE effect, including the more potent BPAP analog ((-)-1-(benzofuran-2-yl)-2-propylaminopentane), has reported lifespan extension in rodents at doses 1,000-fold lower than selegiline (Knoll & Miklya, 2016). Whether the CAE effect can be isolated pharmacologically and tested in humans remains an open research question, with no human studies of BPAP currently registered.

Conclusion

Selegiline occupies a distinctive position among compounds investigated for longevity. It is one of the few pharmaceutical agents with consistent reports of average lifespan extension in multiple mammalian species, accumulated over nearly four decades of laboratory work, and it is supported by an extensive base of clinical safety experience from its established use in Parkinson’s disease and depression. Its core action of preserving dopamine in an aging brain where the catabolic enzyme progressively rises is mechanistically coherent, and supplementary effects on antioxidant defenses, mitochondrial stability, neurotrophic factors, and immune function add plausibility to a broader protective role.

Substantial uncertainty remains. The animal lifespan findings are heterogeneous across strain, sex, and dose. The longevity evidence rests heavily on the original developer’s laboratory and on longevity-industry advocacy, while recent transdermal trials have industry sponsors with commercial interests; these conflicts warrant weight when interpreting both enthusiasm and data. The drug interaction profile, particularly the absolute contraindication with widely prescribed antidepressants and certain over-the-counter cough preparations, represents a real practical barrier and a meaningful safety concern. For health-oriented adults able to safely avoid those interactions, the risk-benefit profile at low oral doses appears favorable on the available evidence base. The picture is one of an unusually well-pedigreed candidate molecule with a long clinical safety history alongside a heterogeneous mammalian lifespan literature.

Top - Benefits - Risks - Protocol

Selegiline for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Symptom Improvement in Parkinson’s Disease

Antidepressant Effect (Transdermal Selegiline)

Medium 🟩 🟩

Lifespan Extension in Mammalian Models ⚠️ Conflicted

Neuroprotective and Cognitive Effects

Low 🟩

Preservation of Dopaminergic Tone in Aging

Immune Function Support

Speculative 🟨

Tumor Manifestation Suppression

Sexual Function and Drive

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Serotonin Syndrome with Concomitant Serotonergic Drugs

Insomnia and Sleep Disturbance

Medium 🟥 🟥

Orthostatic Hypotension

Nausea and Gastrointestinal Effects

Application-Site Reactions (Transdermal)

Low 🟥

Hypertensive Crisis from Tyramine Interaction

Dyskinesia in Patients on Levodopa

Headache and Dizziness

Speculative 🟨

Impulse Control Disorders

Long-Term Effects of Amphetamine Metabolites

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion